Algenics Receives 650k Euros of Oseo Fundings as Part of the Algohub Program, Led by the Roquette Group
ALGENICS SAS has today announced it has been granted OSEO funding amounting to 650,000 Euros for its partnership in the ALGOHUB program, led by the ROQUETTE group.
Nantes, France (PRWEB) November 26, 2008
ALGENICS SAS has today announced it has been granted OSEO funding amounting to 650,000 Euros for its partnership in the ALGOHUB program, led by the ROQUETTE group. This five-year program brings together 14 industrial and academic players in a project aiming to develop microalgae industrial production processes, to enable their value in key markets - such as human and animal nutrition, pharmaceuticals, and cosmetics - to be fully exploited. With the support of OSEO, ALGOHUB's budget will now total 28.4 million Euros, 9.7 million Euros of which is repayable.
"We are particularly pleased to be participating in this ambitious programme in the company of industrial players that have fully understood the huge economic potential of microalgae in sectors as varied as pharmaceuticals, nutrition or cosmetics" explained Morgan Cabigliera, President and co-founder of ALGENICS. "This partnership constitutes a first step along the way to wider recognition of the depth and solidity of our know-how and technologies. This support from ALGOHUB will help sustain our R&D programs in Algebiosys so we can in turn respond optimally to the needs of our industrial partners" he concluded.
"We are delighted to be collaborating with ALGENICS in the framework of ALGOHUB. With its unique expertise in exploiting microalgae in biotechnology, ALGENICS will enable us to accelerate and optimise our projects, to capitalise fully on the use of these micro-organisms in industry" commented Marie-Hélène Saniez, Nutrition Director for the ROQUETTE group.
About ALGENICS:
With its headquarters at Nantes, ALGENICS SAS is the blue biotech company focused on novel uses of eukaryotic microalgae as recombinant protein production system and oral drug delivery system. Founded at the end of 2007, this spin-off from Ifremer has expertise in genetic engineering of microalgae, and exploits these «cellular factories» to fulfil the bioproduction requirements of pharmaceutical, cosmetic and nutraceutical industrials. Its patented technology, Algebiosys, is marketed as a service offering. In parallel, the company develops orally delivered medicines for treating aquaculture populations. Its first product, Algevib fish, is an anti-microbian peptide for treating vibrioses in farmed fish populations. Supported by Atlanpole, ALGENICS is a member of the competitiveness cluster ATLANTIC BIOTHERAPIES and the BLUE CLUSTER, the leading French marine bioresources pole.
Contact:
Morgan Cabigliera, CEO
Email: contact(at)algenics. com
Web: www. algenics. com
About the ROQUETTE group:
Present since1933 on the starch products market, an expert in the processing of agricultural raw materials such as wheat, maize, potato and pea, the ROQUETTE Group (whose head office is located in Lestrem) has built up an image of reliability, innovation and high performance. This family business provides proof every day of the stringency of its high quality standards, the rigour of its research and development approach and its ability to adapt to the changing needs of its customers in the various industrial, food processing, pharmaceutical and cosmetic fields where it is a player. ROQUETTE also has the objective of becoming a major player in the domain of microalgae serving nutrition and health.
Contact:
Philippe CAILLAT
Business Development & Marketing Manager
Nutrition & Health Program
Email: philippe. caillat(at)roquette. com
Web: www. algohub-roquette. com ; www. roquette. com
###
